Market Closed -
Nasdaq
04:00:00 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
4.03
USD
|
+1.00%
|
|
-4.95%
|
-37.13%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
1,758
|
541.5
|
629.2
|
408.9
|
-
|
-
|
Enterprise Value (EV)
1 |
1,201
|
49.27
|
388.3
|
140.8
|
-35.07
|
-191.4
|
P/E ratio
|
-14.8
x
|
-4.54
x
|
-3.36
x
|
-2.33
x
|
-2.41
x
|
-
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
64.3
x
|
19.9
x
|
24.6
x
|
7.07
x
|
8.33
x
|
11.7
x
|
EV / Revenue
|
43.9
x
|
1.81
x
|
15.2
x
|
2.43
x
|
-0.71
x
|
-5.47
x
|
EV / EBITDA
|
-23.7
x
|
-0.36
x
|
-2.42
x
|
-0.98
x
|
0.22
x
|
1.16
x
|
EV / FCF
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
3.12
x
|
1.13
x
|
1.76
x
|
1.92
x
|
3.09
x
|
-
|
Nbr of stocks (in thousands)
|
120,388
|
122,878
|
124,940
|
126,375
|
-
|
-
|
Reference price
2 |
14.61
|
4.407
|
5.036
|
3.235
|
3.235
|
3.235
|
Announcement Date
|
3/23/22
|
3/23/23
|
3/21/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
27.36
|
27.22
|
25.6
|
57.86
|
49.11
|
35
|
EBITDA
1 |
-50.71
|
-135.8
|
-160.4
|
-144.4
|
-158.2
|
-164.8
|
EBIT
1 |
-54.9
|
-145.3
|
-224.3
|
-154.2
|
-168.8
|
-177.4
|
Operating Margin
|
-200.65%
|
-533.71%
|
-876.17%
|
-266.43%
|
-343.81%
|
-506.93%
|
Earnings before Tax (EBT)
|
-
|
-
|
-
|
-
|
-
|
-
|
Net income
1 |
-49.23
|
-118.7
|
-52.4
|
-186
|
-191.5
|
-
|
Net margin
|
-179.94%
|
-436.13%
|
-204.69%
|
-321.41%
|
-390%
|
-
|
EPS
2 |
-0.9900
|
-0.9700
|
-1.500
|
-1.389
|
-1.342
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/23/22
|
3/23/23
|
3/21/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
17.6
|
4.14
|
6.975
|
7.223
|
6.298
|
6.813
|
7.1
|
3.8
|
8.882
|
3.1
|
8
|
20
|
45
|
27
|
EBITDA
|
-3.91
|
-20.96
|
-
|
-
|
-
|
-
|
-
|
-42.85
|
-32.84
|
-42.26
|
-
|
-
|
-
|
-
|
EBIT
1 |
-5.3
|
-22.88
|
-24.7
|
-34.2
|
-41.32
|
-51.31
|
-56.5
|
-59.1
|
-37.22
|
-59.4
|
-42.56
|
-32.06
|
-5.565
|
-25.4
|
Operating Margin
|
-30.11%
|
-552.75%
|
-354.12%
|
-473.56%
|
-656%
|
-753.13%
|
-795.77%
|
-1,555.26%
|
-419.06%
|
-1,916.13%
|
-532.06%
|
-160.32%
|
-12.37%
|
-94.06%
|
Earnings before Tax (EBT)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net income
|
-5.1
|
-20.08
|
-
|
-
|
-
|
-
|
-
|
-45.7
|
-31.21
|
-52.4
|
-
|
-
|
-
|
-
|
Net margin
|
-28.98%
|
-485.12%
|
-
|
-
|
-
|
-
|
-
|
-1,202.63%
|
-351.43%
|
-1,690.32%
|
-
|
-
|
-
|
-
|
EPS
|
-0.0600
|
-0.6700
|
-
|
-
|
-
|
-
|
-
|
-0.3700
|
-0.2500
|
-0.4200
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/17/21
|
3/23/22
|
5/25/22
|
8/17/22
|
11/15/22
|
3/23/23
|
5/24/23
|
8/10/23
|
11/9/23
|
3/21/24
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
557
|
492
|
241
|
268
|
444
|
600
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-15.7%
|
-22.7%
|
-35%
|
-53.4%
|
-80.7%
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
4.680
|
3.880
|
2.860
|
1.690
|
1.050
|
-
|
Cash Flow per Share
2 |
-0.1300
|
-0.5000
|
-0.9500
|
-1.390
|
-1.350
|
-
|
Capex
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/23/22
|
3/23/23
|
3/21/24
|
-
|
-
|
-
|
Last Close Price
3.235
GBP Average target price
6.873
GBP Spread / Average Target +112.44% Consensus |
1st Jan change
|
Capi.
|
---|
| -37.13% | 509M | | +1.51% | 42.75B | | +49.22% | 41.61B | | +8.57% | 41.34B | | -12.36% | 26.59B | | +8.92% | 25.49B | | -25.13% | 18.12B | | +29.17% | 12.24B | | -3.12% | 11.76B | | +6.35% | 11B |
Other Biotechnology & Medical Research
|